This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Cervical Device Contraception-2 (Nanopaz) (NANOPAZ)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2008 by Bnai Zion Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by:
Bnai Zion Medical Center Identifier:
First received: May 19, 2008
Last updated: June 2, 2008
Last verified: June 2008
Measure blood progesterone by using cervical device contraception.

Condition Intervention Phase
Healthy Other: Nanopaz contraception device Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Cervical Device Contraception

Resource links provided by NLM:

Further study details as provided by Bnai Zion Medical Center:

Primary Outcome Measures:
  • blood progesterone measure in blood [ Time Frame: one to two months ]

Estimated Enrollment: 10
Study Start Date: June 2008
Estimated Study Completion Date: May 2010
Estimated Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Nanopaz contraception device
    levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method
    Other Name: levonorgestrel device for cervical contraception-nantechnolgy method
Detailed Description:

A very small cervical device that releases small amount of progesterone 20 mcgm/day.

The target of the research is to measure blood progesterone by using the cervical device.

This small device delivers progesterone by nanotechnology method.


Ages Eligible for Study:   1 Month to 2 Months   (Child)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 10 healthy women are candidate for hysterectomy

Exclusion Criteria:

  • Women with neoplastic malignancy disease or thrombophylia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Baram Paz, Bnai Zion MC Identifier: NCT00689494     History of Changes
Other Study ID Numbers: BnaiZionMC-08-BP-003-CTIL
Study First Received: May 19, 2008
Last Updated: June 2, 2008

Keywords provided by Bnai Zion Medical Center:
Nanopaz device
Blood progesterone measure in using the device
Delivery progesterone
Progesterone levonorgestrel

Additional relevant MeSH terms:
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Contraceptives, Oral, Synthetic
Contraceptives, Oral processed this record on September 21, 2017